Nicole Sandford: Yes. Yes. So I’ll start and then Ryan can add any color to the study. The study is actually — the study that we’re using for the serial monitoring test is actually an extension of the OvaWatch, clinical validation study which is frauds, we continue to take draws and monitor those patients through additional drugs. Our commitment has been to launch that serial monitoring test in the second half of 2023. Ryan, anything else you’d like to add?
Ryan Phan: No, I think that Nicole mentioned everything needed, ask that question. You answered right. I think the OvaWatch serial monitoring assay is going to be key for the patient and the physician as well, particularly for this particular population, many of them was either by selection or by clinically makes sense but not selected for surgical intervention. So they need a tool to follow up and OvaWatch is serving that purpose. The great news is our clinical study has come late but we continue to follow those enrolled patients. So we know exactly what the . So those data are going to help us to set the stage for what the time line and also at the dosage, if you will. If you think therapeutically, how did this frequently how the woman should see the OvaWatch we may have those information when near to the time that we can launch the test which we intended — we remain intended for the second half of the year.
Griffin Soriano: Okay. And then — sorry.
Nicole Sandford: Sorry, let me just say one thing. We understand that in the market that we are in right now but the market conditions being what they are, investors, both current and potential investors, are hyper focused on companies with revenue. We continue to believe that the OvaWatch serial monitoring test is going to drive material revenue for the company and has been really put to the top of the list in terms of things we think about every day. And we do believe that our revenue estimates that we’ve talked about in the past are very, very realistic for a serial monitoring test.
Griffin Soriano: Okay. And then last one, maybe for you, Marlene, on just burn $16 million and $19 million for the year. Anything on how do you think about pacing, first half, second half split? And then I know you had previously sized the reduction forces being maybe something a little over $6 million year-over-year savings in 2023. Is that sort of still how you’re thinking about that?
Marlene McLennan: We are definitely on target for that and monitoring it very closely. It’s pretty evenly spread over the quarters. Most of our savings will be realized towards second quarter going forward, because they were just initiated in first quarter. But overall, we are on target for $16 million to $19 million.
Operator: Ladies and gentlemen, there are no further questions at this time. I’d like to turn the call back to Nicole Sandford for any closing remarks.
Nicole Sandford: Thank you so much and thanks for the questions. We appreciate the attendance today and the continued support and interest in the company. We’ve been through an awful lot of change this year, as I said but I’m more optimistic than I’ve ever been. I’ve said before and I’ll say it again that as companies that are further away from commercialization of their product, are really going to struggle. And as we see the fallout of that happening all around us, I believe that we’re going to be comparatively a very, very attractive investment, especially as we kind of move through the year and we continue to deliver on all of the things that we’ve promised. So, I appreciate your time today and look forward to continuing to bring you additional news and insight as the year goes on. Thank you so much.
Marlene McLennan: Thanks, everyone.
Operator: This concludes today’s conference. You may disconnect your lines at this time. Thank you for your participation and have a great evening.
